Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Advent supports carrhae capital in growth ambitions

Tuesday, March 06, 2012
Opalesque Industry Update:Advent Software, Inc. (NASDAQ: ADVS), a leading provider of software and services for the global investment management industry, today announced that Carrhae Capital LLP has gone live on Advent’s hedge fund solution to support growth and maximize efficiency and transparency.

Based in London, Carrhae Capital was one of the high profile launches of 2011 and is backed by one of the hedge fund industry’s major seeders. Carrhae Capital began implementing Advent‘s solution in mid-October 2011 to benefit from its robust technology and the depth of its functional capabilities, such as real-time dashboards and reports for accurate P&L, streamlined cash, position and transaction reconciliation, and full synthetic equity asset class coverage. Carrhae Capital launched the Carrhae Capital Master Fund in December 2011.

“We chose Advent for the strength of its technology infrastructure, its reputation in the UK hedge fund market and its integration to all the main counterparties, as the most efficient system to help us accelerate our ability to grow our firm,” said Adrian Headon, COO of Carrhae Capital. “We are confident that Advent will help us scale and continually meet the requirements of the most demanding institutional investors.”

“Being selected by Carrhae Capital further validates Advent’s reputation in the UK hedge fund market as a leading portfolio management solution, and underscores our growing success and traction with local firms,” said Håkan Valberg, senior vice president and general manager, Advent Software EMEA. “The rapid time to market and low cost of ownership reinforce the continued appeal of our solutions for startup hedge funds in the UK.”

Advent Software

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for